Company: TELO
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001641172-25-013196
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-06-02
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
June 2, 2025, Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“ Telomir” or the “ Company”) announced that it will
participate in the BIO International Convention 2025, taking place in Boston, Massachusetts from June 16 - 19, 2025. The Company
has scheduled a full week of BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and
M& A opportunities.

Separately,
the Company is providing an update on the continued progress of its lead candidate, Telomir-1

The
Company also reported significant preclinical progress across multiple programs. These include:

  Retinal                                                                                           
  Lifespan                                                                                          
  Reversal                                                                                          
  Anti-cancer                                                                                       
  Ion-binding                                                                                       
  The                                                                                               

In
addition, Telomir has launched a rare disease development initiative targeting orphan indications such as Werner’s syndrome Wilson’s disease Progeria dysphonia autism spectrum disorder

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    TELOMIR                                       
  Dated:            By:                        /s/                
                    Name:                      Erez               
                    Title:                     Chief